AR070816A1 - Farmaco de combinacion para tratar trastornos vasculares - Google Patents

Farmaco de combinacion para tratar trastornos vasculares

Info

Publication number
AR070816A1
AR070816A1 ARP090100806A ARP090100806A AR070816A1 AR 070816 A1 AR070816 A1 AR 070816A1 AR P090100806 A ARP090100806 A AR P090100806A AR P090100806 A ARP090100806 A AR P090100806A AR 070816 A1 AR070816 A1 AR 070816A1
Authority
AR
Argentina
Prior art keywords
combination
salt
arterial disease
carbostiryl
pharmaco
Prior art date
Application number
ARP090100806A
Other languages
English (en)
Inventor
Kensuke Orito
Hiroshi Ohno
Takao Urabe
Yuji Ueno
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41065644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR070816(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR070816A1 publication Critical patent/AR070816A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Una combinacion caracterizada porque comprende como componentes activos un derivado de carbostirilo de la formula general (1) donde A es un grupo alquileno inferior, R es un grupo cicloalquilo, el enlace entre las posiciones 3 y 4 del esqueleto del carbostirilo es un enlace simple o un enlace doble, o una sal del mismo; y carnitina o una sal de la misma. Reivindicacion 2: La combinacion de la reivindicacion 1 caracterizada porque el derivado de carbostirilo es 6-[4-(1-ciclohexil-1H-tetrazol-5-il)butoxi]-3,4- dihidrocarbostirilo o una sal del mismo. Reivindicacion 3: Un medicamento para tratar la enfermedad arterial periférica oclusiva, caracterizado porque comprende la combinacion de la reivindicacion 1 o 2. Reivindicacion 5: El medicamento de la reivindicacion 3 o 4 caracterizado porque la enfermedad arterial periférica oclusiva es una enfermedad arterial oclusiva aguda, tromboangeítis obliterante, arteriosclerosis obliterante, estenosis espinal lumbar, o claudicacion intermitente.
ARP090100806A 2008-03-14 2009-03-06 Farmaco de combinacion para tratar trastornos vasculares AR070816A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008065448 2008-03-14
JP2008118289 2008-04-30

Publications (1)

Publication Number Publication Date
AR070816A1 true AR070816A1 (es) 2010-05-05

Family

ID=41065644

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100806A AR070816A1 (es) 2008-03-14 2009-03-06 Farmaco de combinacion para tratar trastornos vasculares

Country Status (14)

Country Link
US (2) US8980919B2 (es)
EP (1) EP2254578A2 (es)
JP (2) JP5574989B2 (es)
KR (1) KR101632448B1 (es)
CN (2) CN102026638B (es)
AR (1) AR070816A1 (es)
AU (1) AU2009224214B2 (es)
BR (1) BRPI0909291A8 (es)
CA (1) CA2717351A1 (es)
CL (1) CL2009000589A1 (es)
PE (1) PE20091675A1 (es)
RU (1) RU2506950C2 (es)
TW (1) TW200944204A (es)
WO (1) WO2009113741A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933205B (zh) 2010-04-28 2014-08-13 诺弗米克斯有限公司 西洛他唑共晶和组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
AU1295700A (en) * 1998-11-26 2000-06-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
DE60103668T2 (de) * 2001-02-07 2005-06-09 Disa Industries A/S Sandgiessmaschine mit verbessertem sandblasen
US20060160896A1 (en) * 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
AR057520A1 (es) * 2005-09-15 2007-12-05 Otsuka Pharma Co Ltd Farmaco combinado

Also Published As

Publication number Publication date
RU2506950C2 (ru) 2014-02-20
CN102026638B (zh) 2015-06-24
BRPI0909291A8 (pt) 2016-07-12
US20150150865A1 (en) 2015-06-04
AU2009224214A1 (en) 2009-09-17
RU2010141982A (ru) 2012-04-20
AU2009224214B2 (en) 2013-12-12
JP5574989B2 (ja) 2014-08-20
JP5837128B2 (ja) 2015-12-24
JP2011513480A (ja) 2011-04-28
PE20091675A1 (es) 2009-11-16
KR20100123909A (ko) 2010-11-25
CL2009000589A1 (es) 2010-03-26
BRPI0909291A2 (pt) 2015-08-11
KR101632448B1 (ko) 2016-06-21
JP2014159458A (ja) 2014-09-04
CA2717351A1 (en) 2009-09-17
US20110015224A1 (en) 2011-01-20
CN102026638A (zh) 2011-04-20
WO2009113741A2 (en) 2009-09-17
EP2254578A2 (en) 2010-12-01
CN104906097A (zh) 2015-09-16
TW200944204A (en) 2009-11-01
WO2009113741A3 (en) 2010-04-29
US8980919B2 (en) 2015-03-17

Similar Documents

Publication Publication Date Title
AR066664A1 (es) Un medicamento para tratar enfermedad de alzheimer
CU20120015A7 (es) Piridina y pirazina como derivados de moduladores de la proteína kinasa
CR20160269A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento del cancer y enfermedades comunes
CR20120289A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
WO2015086406A3 (en) Factor ix variants with clotting activity in absence of their cofactor and/or with increased f.ix clotting activity and their use for treating bleeding disorders
ATE530526T1 (de) Lactam-substituierte dicarbonsäuren und ihre verwendung
DOP2012000174A (es) Metodo de tratamiento
EA201792597A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
WO2015091414A3 (de) Substituierte piperidinyl-tetrahydrochinoline und ihre verwendung als alpha-2c adrenorezeptor antagonisten
EA200970948A1 (ru) Антиангиогенные агенты и способы их применения
AR092247A1 (es) INHIBIDORES DE LA b-SECRETASA
AR067446A1 (es) Un medicamento para tratar higado graso que comprende cilostazol
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
BR112015022849A2 (pt) sais de adição de base de nitroxolina e usos dos mesmos
AR070816A1 (es) Farmaco de combinacion para tratar trastornos vasculares
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca
ATE545340T1 (de) Konzentrierte cipc-formulierungen in dialkylenglykolen und deren verwendung in der keimungshemmenden behandlung von zwiebeln oder knollen
AR067746A1 (es) Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol
AR065855A1 (es) Un medicamento para tratar la esquizofrenia que comprende cilostazol
GT200800169A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
AR065588A1 (es) Un medicamento para tratar enfermedad pulmonar obstructiva cronica
UY32827A (es) Inhibidores de catepsina c

Legal Events

Date Code Title Description
FB Suspension of granting procedure